Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vasee Moorthy

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
The Lancet. Infectious Diseases|August 8, 2015
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialAngela Huttner, Julie-Anne Dayer, Sabine Yerly, et al.
The Lancet. Infectious Diseases|January 5, 2016
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a studyOlga De Santis, Régine Audran, Emilie Pothin, et al.
Plos Medicine|October 7, 2017
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trialSelidji T Agnandji, José F Fernandes, Emmanuel B Bache, et al.
The Lancet. Infectious Diseases|November 8, 2015
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trialMilagritos D Tapia, Samba O Sow, Kirsten E Lyke, et al.
The New England Journal of Medicine|April 2, 2015
Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeSelidji T Agnandji, Angela Huttner, Madeleine E Zinser, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
The Lancet. Infectious Diseases|August 8, 2015
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialAngela Huttner, Julie-Anne Dayer, Sabine Yerly, et al.
The Lancet. Infectious Diseases|January 5, 2016
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a studyOlga De Santis, Régine Audran, Emilie Pothin, et al.
Plos Medicine|October 7, 2017
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trialSelidji T Agnandji, José F Fernandes, Emmanuel B Bache, et al.
The Lancet. Infectious Diseases|November 8, 2015
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trialMilagritos D Tapia, Samba O Sow, Kirsten E Lyke, et al.
The New England Journal of Medicine|April 2, 2015
Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeSelidji T Agnandji, Angela Huttner, Madeleine E Zinser, et al.
Pageof 5